Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma
International Journal of Dermatology · 2024
DOI: 10.1111/ijd.17285 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Marek Pásek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech …. Hauptthemen laut MEDLINE: Melanoma, Antibodies, Monoclonal, Humanized, Phenylurea Compounds, Quinolines. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic.
- Department of Oncology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic.
ORCID-Profile: Marek Pásek, Emanuel Marques, Jiří Švec, Petr Arenberger, Monika Arenbergerová
Zitieren
APA
Pásek, M., Marques, E., Švec, J., Arenberger, P., & Arenbergerová, M. (2024). Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma. International Journal of Dermatology. https://doi.org/10.1111/ijd.17285
Vancouver
Pásek M, Marques E, Švec J, Arenberger P, Arenbergerová M. Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma. International Journal of Dermatology. 2024. doi:10.1111/ijd.17285
BibTeX
@article{Psek2024,
author = {Pásek, Marek and Marques, Emanuel and Švec, Jiří and Arenberger, Petr and Arenbergerová, Monika},
title = {Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma},
journal = {International Journal of Dermatology},
year = {2024},
doi = {10.1111/ijd.17285}
}
EUVIMED